Keyphrases
Patient-derived Xenograft
100%
Mammalian Target of Rapamycin (mTOR)
100%
Breast Cancer
100%
Basal-like
100%
Effective Strategies
100%
Combined Targeting
100%
Cancer Inpatients
100%
MK-2206
71%
Knockdown
42%
Phosphatidylinositol 3-kinase Pathway
42%
Cell Proliferation
28%
Tumor Cells
28%
Angiogenesis
28%
Synergistic Effect
28%
Pathway Inhibitors
28%
Immunohistochemistry
14%
Breast Cancer Cell Lines
14%
Cell Growth
14%
Tumor Growth
14%
Targeted Therapy
14%
Tumor Volume
14%
Cell Tumor
14%
Clinical Investigation
14%
Akt Phosphorylation
14%
Therapeutic Potential
14%
Antitumor Effect
14%
Biomarker Studies
14%
Aggressive Disease
14%
Increased Activity
14%
Tumor Inhibition
14%
Cell Sensitivity
14%
CD31
14%
Akt Activation
14%
Ther
14%
Two-agent
14%
PTEN Expression
14%
Biochemistry, Genetics and Molecular Biology
Phosphoinositide 3-Kinase
100%
Protein Kinase B
100%
Mammalian Target of Rapamycin
100%
Tumor Progression
66%
Angiogenesis
66%
Cell Proliferation
66%
Cancer Cell
33%
Cell Growth
33%
Biomarker Study
33%
Growth Inhibition
33%
Tumor Volume
33%
CD31
33%
Medicine and Dentistry
Xenograft
100%
Mammalian Target of Rapamycin
100%
Protein Kinase B
100%
Basal Like Breast Cancer
100%
Phosphoinositide 3-Kinase
42%
Cell Proliferation
28%
Tumor Cell
28%
Angiogenesis
28%
Malignant Neoplasm
14%
Neoplasm
14%
Immunohistochemistry
14%
In Vitro
14%
Cell Growth
14%
Targeted Therapy
14%
Biomarker Study
14%
Tumor Progression
14%
Cancer Inhibition
14%
Breast Cancer Cell Line
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Kinase B
100%
Basal Like Breast Cancer
100%
Phosphatidylinositol 3 Kinase
42%
Neoplasm
28%
Tumor Growth
14%
Malignant Neoplasm
14%
Biomarker Study
14%
Cancer Inhibition
14%
Diseases
14%